313 related articles for article (PubMed ID: 23903844)
1. Preferential HIV infection of CCR6+ Th17 cells is associated with higher levels of virus receptor expression and lack of CCR5 ligands.
Alvarez Y; Tuen M; Shen G; Nawaz F; Arthos J; Wolff MJ; Poles MA; Hioe CE
J Virol; 2013 Oct; 87(19):10843-54. PubMed ID: 23903844
[TBL] [Abstract][Full Text] [Related]
2. Memory CCR6+CD4+ T cells are preferential targets for productive HIV type 1 infection regardless of their expression of integrin β7.
Monteiro P; Gosselin A; Wacleche VS; El-Far M; Said EA; Kared H; Grandvaux N; Boulassel MR; Routy JP; Ancuta P
J Immunol; 2011 Apr; 186(8):4618-30. PubMed ID: 21398606
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection.
El Hed A; Khaitan A; Kozhaya L; Manel N; Daskalakis D; Borkowsky W; Valentine F; Littman DR; Unutmaz D
J Infect Dis; 2010 Mar; 201(6):843-54. PubMed ID: 20144043
[TBL] [Abstract][Full Text] [Related]
4. Toll-Like Receptor 2 Ligation Enhances HIV-1 Replication in Activated CCR6+ CD4+ T Cells by Increasing Virus Entry and Establishing a More Permissive Environment to Infection.
Bolduc JF; Ouellet M; Hany L; Tremblay MJ
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928019
[TBL] [Abstract][Full Text] [Related]
5. Human Beta Defensin 2 Selectively Inhibits HIV-1 in Highly Permissive CCR6⁺CD4⁺ T Cells.
Lafferty MK; Sun L; Christensen-Quick A; Lu W; Garzino-Demo A
Viruses; 2017 May; 9(5):. PubMed ID: 28509877
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel HIV-1 dependency factors in primary CCR4(+)CCR6(+)Th17 cells via a genome-wide transcriptional approach.
Cleret-Buhot A; Zhang Y; Planas D; Goulet JP; Monteiro P; Gosselin A; Wacleche VS; Tremblay CL; Jenabian MA; Routy JP; El-Far M; Chomont N; Haddad EK; Sekaly RP; Ancuta P
Retrovirology; 2015 Dec; 12():102. PubMed ID: 26654242
[TBL] [Abstract][Full Text] [Related]
7. Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection.
Gosselin A; Monteiro P; Chomont N; Diaz-Griffero F; Said EA; Fonseca S; Wacleche V; El-Far M; Boulassel MR; Routy JP; Sekaly RP; Ancuta P
J Immunol; 2010 Feb; 184(3):1604-16. PubMed ID: 20042588
[TBL] [Abstract][Full Text] [Related]
8. Expression of chemokine receptors CCR5 and CXCR4 on CD4+ T cells and plasma chemokine levels during treatment of active tuberculosis in HIV-1-coinfected patients.
Wolday D; Tegbaru B; Kassu A; Messele T; Coutinho R; van Baarle D; Miedema F
J Acquir Immune Defic Syndr; 2005 Jul; 39(3):265-71. PubMed ID: 15980685
[TBL] [Abstract][Full Text] [Related]
9. Identification of an unique CXCR4 epitope whose ligation inhibits infection by both CXCR4 and CCR5 tropic human immunodeficiency type-I viruses.
Adachi T; Tanaka R; Kodama A; Saito M; Takahashi Y; Ansari AA; Tanaka Y
Retrovirology; 2011 Oct; 8():84. PubMed ID: 22018245
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1.
Xiang J; George SL; Wünschmann S; Chang Q; Klinzman D; Stapleton JT
Lancet; 2004 Jun; 363(9426):2040-6. PubMed ID: 15207954
[TBL] [Abstract][Full Text] [Related]
11. Limited expression of R5-tropic HIV-1 in CCR5-positive type 1-polarized T cells explained by their ability to produce RANTES, MIP-1alpha, and MIP-1beta.
Annunziato F; Galli G; Nappi F; Cosmi L; Manetti R; Maggi E; Ensoli B; Romagnani S
Blood; 2000 Feb; 95(4):1167-74. PubMed ID: 10666186
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a human cervical CD4+ T cell subset coexpressing multiple markers of HIV susceptibility.
McKinnon LR; Nyanga B; Chege D; Izulla P; Kimani M; Huibner S; Gelmon L; Block KE; Cicala C; Anzala AO; Arthos J; Kimani J; Kaul R
J Immunol; 2011 Dec; 187(11):6032-42. PubMed ID: 22048765
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of HIV coreceptors CXCR4 and CCR5 on CD4(+) T cells during human endotoxemia and after stimulation with (myco)bacterial antigens: the role of cytokines.
Juffermans NP; Paxton WA; Dekkers PE; Verbon A; de Jonge E; Speelman P; van Deventer SJ; van der Poll T
Blood; 2000 Oct; 96(8):2649-54. PubMed ID: 11023494
[TBL] [Abstract][Full Text] [Related]
14. CD161 identifies polyfunctional Th1/Th17 cells in the genital mucosa that are depleted in HIV-infected female sex workers from Nairobi, Kenya.
Boily-Larouche G; Omollo K; Cheruiyot J; Njoki J; Kimani M; Kimani J; Oyugi J; Lajoie J; Fowke KR
Sci Rep; 2017 Sep; 7(1):11123. PubMed ID: 28894259
[TBL] [Abstract][Full Text] [Related]
15. Th17 CD4+ T-Cell as a Preferential Target for HIV Reservoirs.
Renault C; Veyrenche N; Mennechet F; Bedin AS; Routy JP; Van de Perre P; Reynes J; Tuaillon E
Front Immunol; 2022; 13():822576. PubMed ID: 35197986
[TBL] [Abstract][Full Text] [Related]
16. IFN-gamma and IL-12 differentially regulate CC-chemokine secretion and CCR5 expression in human T lymphocytes.
Losana G; Bovolenta C; Rigamonti L; Borghi I; Altare F; Jouanguy E; Forni G; Casanova JL; Sherry B; Mengozzi M; Trinchieri G; Poli G; Gerosa F; Novelli F
J Leukoc Biol; 2002 Oct; 72(4):735-42. PubMed ID: 12377943
[TBL] [Abstract][Full Text] [Related]
17. Human Th17 Cells Lack HIV-Inhibitory RNases and Are Highly Permissive to Productive HIV Infection.
Christensen-Quick A; Lafferty M; Sun L; Marchionni L; DeVico A; Garzino-Demo A
J Virol; 2016 Sep; 90(17):7833-47. PubMed ID: 27334595
[TBL] [Abstract][Full Text] [Related]
18. Viral and Cellular Factors Leading to the Loss of CD4 Homeostasis in HIV-1 Viremic Nonprogressors.
Colomer-Lluch M; Kilpelainen A; Pernas M; Peña R; Ouchi D; Jimenez-Moyano E; Dalmau J; Casado C; López-Galíndez C; Clotet B; Martinez-Picado J; Prado JG
J Virol; 2022 Jan; 96(1):e0149921. PubMed ID: 34668779
[TBL] [Abstract][Full Text] [Related]
19. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus.
Shah K; Lee WW; Lee SH; Kim SH; Kang SW; Craft J; Kang I
Arthritis Res Ther; 2010; 12(2):R53. PubMed ID: 20334681
[TBL] [Abstract][Full Text] [Related]
20. Changes in CCR5 and CXCR4 expression and beta-chemokine production in HIV-1-infected patients treated with highly active antiretroviral therapy.
Pierdominici M; Giovannetti A; Ensoli F; Mazzetta F; Marziali M; De Cristofaro MR; Santini-Muratori D; Leti W; Aiuti F
J Acquir Immune Defic Syndr; 2002 Feb; 29(2):122-31. PubMed ID: 11832680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
